Treatment of patients with diabetes who require insulin to maintain normal Glucose metabolism. The indication for the use of the preparation is also the initial period of diabetes and diabetes in pregnant women.
The preparation is a suspension of soluble insulin obtained by the recombination of bacterial DNAE. coli. Insulin reduces blood Glucose, exerts anabolic and anti-catabolic action, increases glucose transport into cells and enhances glycogen synthesis in muscle tissue and liver, reduces glycogenolysis and gluconeogenesis, increases lipogenesis in liver and fat tissue, inhibits lipolysis, increases amino acid uptake and protein synthesis . The product contains human insulin with a rapid onset and short duration of action. The onset of action occurs after 30 minutes, the maximum hypoglycaemic effect within 1-3 hours; the total duration of action is 6-8 h.
Contraindications:
Hypoglycemia. Hypersensitivity to the active substance or any of the excipients unless it is part of the desensitization program.
Precautions:
Changing the type or brand of insulin used may result in the need to modify the dosage - strict medical supervision is advisable. In patients who have improved glycemic control significantly, the warning symptoms of hypoglycaemia may be less pronounced or not appear at all. Other situations that may change or diminish the early warning symptoms of hypoglycaemia: the period after the change of animal-derived insulin to human long-term diabetes, diabetic neuropathy, the concomitant use of certain drugs (eg beta-blockers). The need for insulin can change significantly in the case of diseases of the adrenal glands, pituitary gland, thyroid gland, kidney and liver disorders. The need for insulin can be increased during diseases or emotional disorders. Dose modification may also be necessary in the event of a change in the patient's physical activity or diet. Cases of heart failure have been reported during the concomitant use of insulin and pioglitazone, particularly in patients with risk factors for heart failure. This should be borne in mind before using combination therapy with human insulin with pioglitazone. For combination therapy, patients should be monitored for signs and symptoms of heart failure, weight gain and edema. If cardiovascular symptoms worsen, the use of pioglitazone should be discontinued.
Pregnancy and lactation:
The preparation can be used during pregnancy. In pregnant women with diabetes, it is necessary to closely monitor the level of glucose and overall health. The insulin requirement usually decreases in the first trimester and increases during the second and third trimester of pregnancy. Patients with breast-feeding diabetes may need to modify the dose and / or diet.
Side effects:
The most common side effect is hypoglycaemia. Common: allergic reaction at the injection site (erythema swelling, pruritus). Uncommon: Lipodystrophy at the injection site (regular change of the injection site may prevent or reduce the occurrence of this reaction). Very rare: Systemic symptoms of hypersensitivity. During edema treatment, edema has been reported, especially if previously observed insufficient metabolic control has been improved as a result of intensive insulin therapy.
Dosage:
Individually, according to the need for insulin. The product is administered under the skin subcutaneously in the upper arm, thigh, buttock or stomach. Places of injection should be changed so that the same place is not used more often than about once a month. Although it is not recommended, the preparation can be given by intramuscular injection. In special circumstances, it can be administered intravenously. Make sure that you do not insert the needle into a blood vessel while administering any insulin. After injecting insulin, do not massage the injection site.
(C)
